AltheaDx employs Wendy Benson as CEO
This article was originally published in Clinica
Molecular diagnostics firm AltheaDx has appointed Wendy Benson to the position of CEO and president. She will replace interim co-CEOs, Dr François Ferré and Dr Magda Marquet, who will remain at the firm as co-chairs on the company’s board. Ms Benson was recently president and CEO at infectious disease specialist HX Diagnostics and has previously worked at Roche Molecular Diagnostics, Ortho Clinical Diagnostics and Genetic Systems. Ms Benson will also join AltheaDx’s board of directors along with Ann Kessler, former director of international project management at Hoffman-La Roche. Dr Kessler joins the firm as an independent director.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals